Wolfgang Miesbach: What Goes Wrong When Approved Gene Therapies Get Withdrawn?
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Ana Hidalgo-Simon and Claire Booth, published in Blood ICT:
”Gene therapy approved. Gene therapy withdrawn. What went wrong?
38% of all approved ATMPs in the EU have been withdrawn – not because they failed, but because the commercial model collapsed.
Zynteglo for β-thalassemia had orphan designation, PRIME status, conditional approval, accelerated assessment – and was still pulled from the market in 2022 when reimbursement negotiations failed.
Beqvez for haemophilia B: same story.
Why?
- Most gene therapies are born in academia – outstanding science, but commercial planning is not the focus
- Health systems run on chronic care budgets – a large one-off payment for a cure simply doesn’t fit
- Post-approval requirements aren’t scaled for ultrarare diseases, making the economics brutal even after approval
What the authors propose is worth taking seriously:
- Charitable foundations as marketing authorization holders — Telethon took over Strimvelis from Orchard Therapeutics in 2023, the first such transfer for an ATMP
- The AGORA Foundation enabling cross-border access to proven therapies across Europe
- Public benefit corporations like Rarity (US) advancing ADA-SCID gene therapy
- Hospital exemption pathways as a structured route for ultrarare diseases
- EU joint clinical assessments now operational from 2025 — a first step toward harmonized reimbursement
For haemophilia, this is not hypothetical – it is happening now.
The lessons from immune deficiency gene therapy are directly relevant to where we stand with hemophilia A and B gene therapies today.
Congratulations to the authors Ana Hidalgo-Simon and Claire Booth.”
Title: Advancing ATMPs for orphan diseases: redefining the roles of pharmaceutical companies and academia
Authors: Ana Hidalgo-Simon, Claire Booth
Read the Full Article on Blood ICT
Stay updated on all scientific advances with Hemostasis Today.
-
May 22, 2026, 15:02Robert Brodsky: Can You Stop Thrombosis and Treat CAPS Without Anticoagulation?
-
May 22, 2026, 14:50Eric Topol: New Nature Editorial on the Limits and Promise of AI Scientists
-
May 22, 2026, 14:40Harry Spoelstra: Omicron COVID-19 and Coronary Thrombosis Without Atherosclerosis
-
May 22, 2026, 14:21Clinical Challenges in Thrombosis III – Thrombosis Canada
-
May 22, 2026, 14:03Wolfgang Miesbach: Exploring the Role of Micronutrients in Healthy Longevity
-
May 22, 2026, 13:53Masoabi Sefojane: The Structural Invisibility of Bleeding Disorders in the Global South
-
May 22, 2026, 13:41Ney Carter Borges: New Trial Highlights IVL as Effective Strategy for Calcified Coronary Lesions
-
May 22, 2026, 13:36Ajay Samkaria։ A Compatible Crossmatch Does Not Always Mean Complete Safety
-
May 22, 2026, 13:31Mariam Swidan: Why Hemolysis Severity Matters in G6PD Deficiency